Gain Therapeutics, Inc. develops allosteric small molecule therapies for neurodegenerative and other difficult-to-treat diseases. The company’s lead candidate, GT-02287, is being developed for Parkinson’s disease with or without a GBA1 mutation and is designed as a brain-penetrant allosteric enzyme modulator of glucocerebrosidase, or GCase.
Recurring news for GANX includes financial results, corporate updates, clinical and biomarker data for GT-02287, FDA and IND-related communications, and scientific presentations at Parkinson’s and neurodegeneration conferences. Company updates also cover the Magellan™ drug discovery platform, preclinical GCase modulator programs such as GT-04686, and pipeline areas including lysosomal storage disorders, metabolic diseases and solid tumors.
Gain Therapeutics (Nasdaq: GANX) will participate in the 2026 Maxim Growth Summit, taking place October 12–14 in New York City.
The event will be held at The Hard Rock Hotel New York. Gain will meet institutional investors in one-on-one sessions and engage with senior Maxim research analysts. Those interested in meeting management can contact their Maxim sales representative to schedule.
Gain Therapeutics (Nasdaq: GANX) reported stable Parkinson’s motor scores through 12 months of rexaceract dosing in its Phase 1b open-label extension. Among 12 evaluable participants who completed dosing by August 31, 2026, MDS-UPDRS Parts II and III, measures of daily motor function and clinician-assessed symptoms, showed no clinically meaningful progression from baseline. Scores remained stable in groups with both high and low baseline cerebrospinal-fluid GluSph, a biological marker. The high-baseline group also showed reduced GluSph after 90 days.
Preliminary safety data showed no new safety signals and fewer treatment-emergent adverse events in the nine-month extension than in the initial three months. Gain expects to submit a new Phase 2 protocol to the FDA in the coming weeks and has moved the planned trial start to 1Q27 to incorporate Phase 1b findings.
Gain Therapeutics (GANX) announced a poster presentation on GT-02287 (Rexaceract) in people with Parkinson’s disease, scheduled for October 7, 2026.
The poster covers long-term open-label data. It will be presented from 12:00–12:10pm KST at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul, Korea. E-Poster 753 will appear at Station 12 in Hall D, 3rd Floor.
Gain Therapeutics (GANX) will participate in the ROTH Fifth Annual Healthcare Opportunities Conference on September 29, 2026, at the Metropolitan Club in New York, NY. President and CEO Gene Mack will join an industry panel titled “Frontiers in Neuroscience” scheduled for 11:00 a.m. ET, and the company will also hold one-on-one meetings with registered attendees.
Gain Therapeutics (Nasdaq: GANX) announced that President and CEO Gene Mack will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York City.
An on-demand company presentation will be available on Friday, September 11, 2026, with replay access starting at 7:00 a.m. ET for 90 days via the “Investors & Media/News & Events” section of the company’s website. Registered attendees can request one-on-one meetings through H.C. Wainwright, while others may contact ir@gaintherapeutics.com to arrange discussions with management.
Gain Therapeutics (Nasdaq: GANX) reported Q2 2026 results and a corporate update, highlighted by FDA acceptance of its IND for lead Parkinson’s candidate rexaceract (GT-02287), enabling planned initiation of a Phase 2 trial in the U.S. in Q3 2026.
Phase 1b interim extension data in 16 Parkinson’s patients showed stable MDS‑UPDRS scores through at least Day 150, with greater benefit in those with high baseline CSF GluSph and continued non‑progression signals through Days 270 and 360. Second asset GT‑04686 is progressing toward IND‑enabling studies, with initial indication selection expected by year end.
Q2 2026 R&D expenses were $2.1 million versus $2.8 million a year earlier, while G&A expenses rose to $2.5 million from $2.3 million. Net loss was $4.7 million, or $0.11 per share, compared with $5.8 million, or $0.19 per share, in Q2 2025. Cash and cash equivalents totaled $13.1 million as of June 30, 2026.
Gain Therapeutics (Nasdaq: GANX) CEO Gene Mack issued a shareholder letter outlining clinical, pipeline, organizational and financial updates. The company’s lead Parkinson’s disease candidate rexaceract completed 150 days of dosing in a Phase 1b open-label extension, with all 16 participants remaining on study and an independent Data Monitoring Committee recommending continuation without modification. Earlier 90-day data showed an average 81% reduction in cerebrospinal fluid GluSph among participants with elevated baseline levels, alongside decreased DOPA decarboxylase and stabilized or improved MDS-UPDRS scores, including a 4.8-point difference favoring those with high baseline GluSph. The FDA has authorized an IND, and a Phase 2 trial in early Parkinson’s is expected to begin in 3Q26. Gain is also advancing second GCase modulator GT-04686 toward IND-enabling studies and promoted Joanne Taylor to Chief Scientific Officer and Terenzio Ignoni to Chief Operating Officer. As of March 31, 2026, cash and equivalents were $16.5 million, which the company expects will fund operations into 2Q27, including completion of the Phase 1b extension and initiation of Phase 2.
Gain Therapeutics (Nasdaq: GANX) received FDA clearance of its IND for GT-02287, allowing Phase 2 development in Parkinson’s disease with or without GBA1 mutation in the U.S. Phase 2a initiation is expected in 3Q26 across the U.S., Australia, and Europe.
Phase 1b extension data showed sustained target engagement, including an average 81% CSF GluSph reduction at 90 days in participants with elevated baseline levels, favorable safety and tolerability through five months, and stable or improved motor scores.
Gain Therapeutics (Nasdaq: GANX) announced that President and CEO Gene Mack will join a virtual fireside chat and one-on-one meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, held June 15-16, 2026.
The fireside chat replay starts June 15, 2026, at 7:00 a.m. EDT and will be accessible via the event link or the company’s “Investors & Media/News & Events” webpage. Registered attendees can request one-on-one meetings with Gain management through H.C. Wainwright, while others may email ir@gaintherapeutics.com to arrange discussions.
Gain Therapeutics (Nasdaq: GANX) reported positive interim data from its Phase 1b study of GT-02287 in idiopathic and GBA1 Parkinson’s disease, presented at the 3rd International GBA1 Meeting 2026.
All 16 extension participants completed 150 days of dosing with stable MDS-UPDRS scores overall and a 4.8-point Part II+III difference favoring patients with high baseline CSF GluSph. According to Gain Therapeutics, CSF GluSph fell 81% after 90 days in patients with elevated baseline levels, with accompanying DDC decreases. Participants also commonly reported perceived improvements in smell and taste, balance or gait, and sleep. A Data Monitoring Committee recommended the study continue unchanged, and a Phase 2 trial is planned with objective smell and gait endpoints.